


**LISTING OF CLAIMS**

Claim 1. (Original) A compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein

Y is

- a)  $\text{-NHC(=W)R}^1$ ,
- b)  $\text{-O-het}$ ,  $\text{-S-het}$ , or  $\text{-NH-het}$ ;

X is

- a)  $\text{-O-}$ ,
- b)  $\text{-NR}^3\text{-}$ ,
- c)  $\text{-S(=O)}_i\text{-}$ , or
- d)  $\text{-S(=O)(=NR}^4\text{)-}$ ;

W is

- a) O, or
- b) S;

$\text{R}^1$  is

- a) H,
- b)  $\text{C}_{1-8}\text{alkyl}$ ,
- c)  $\text{C}_{3-6}\text{cycloalkyl}$ ,
- d)  $\text{OC}_{1-4}\text{ alkyl}$ ,
- e)  $\text{SC}_{1-4}\text{ alkyl}$ ,
- f)  $\text{NH}_2$ ,
- g)  $\text{NHC}_{1-6}\text{ alkyl}$ , or
- h)  $\text{N(C}_{1-6}\text{ alkyl)}_2$ ;

$\text{R}^2$  is

- a) H,
- b) halo, or
- c) C<sub>1-4</sub> alkyl;

R<sup>3</sup> is

- a) H,
- b) C<sub>1-8</sub>alkyl,
- c) aryl,
- d) het,
- e) C(=W)R<sup>5</sup>,
- f) C(=O)OR<sup>6</sup>, or
- g) S(=O)<sub>i</sub>R<sup>7</sup>;

R<sup>4</sup> is

- a) H, or
- b) C<sub>1-8</sub>alkyl;

R<sup>5</sup> is

- a) H,
- b) aryl,
- c) het,
- d) NR<sup>8</sup>R<sup>9</sup>, or
- e) C<sub>1-8</sub>alkyl;

R<sup>6</sup> is

- a) C<sub>1-8</sub>alkyl,
- b) aryl, or
- c) het;

R<sup>7</sup> is

- a) aryl,
- b) het,
- c) NR<sup>8</sup>R<sup>9</sup>, or
- d) C<sub>1-8</sub>alkyl;

R<sup>8</sup> and R<sup>9</sup> are independently

- a) H,
- b) C<sub>1-8</sub>alkyl, or
- c) aryl;

wherein >G-E- is >N-C- and Q is a carbon atom, or >G-E is >C=C- and Q is a nitrogen atom;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;

het is a C-linked five- (5) or six- (6) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring;

at each occurrence, alkyl or cycloalkyl is optionally substituted with one or more OR<sup>8</sup>, halo, aryl, S(=O)<sub>i</sub>R<sup>7</sup>, C(=W)R<sup>8</sup>, OC(=O)C<sub>1-6</sub>alkyl, or NR<sup>8</sup>R<sup>9</sup>;

at each occurrence, aryl is optionally substituted with one or more halo, OH, CF<sub>3</sub>, OC<sub>1-6</sub>alkyl, CN, C<sub>1-6</sub>alkyl, S(=O)<sub>i</sub>R<sup>7</sup>, C(=W)R<sup>8</sup>, OC(=O)R<sup>8</sup>, NHC(=O)R<sup>8</sup>, or NR<sup>8</sup>R<sup>9</sup>;


at each occurrence, het is optionally substituted with one or more halo, OH, CF<sub>3</sub>, OC<sub>1-6</sub>alkyl, CN, C<sub>1-6</sub>alkyl, S(=O)<sub>i</sub>R<sup>7</sup>, C(=W)R<sup>8</sup>, OC(=O)R<sup>8</sup>, NHC(=O)R<sup>8</sup>, or NR<sup>8</sup>R<sup>9</sup>, oxo, or oxime;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, 3, or 4; with the proviso that m and n taken together are 3 or 4; and

i is 0, 1, or 2.

Claim 2. (Original) A compound of claim 1 which is a compound of formula IA:



IA.

Claim 3. (Original) A compound of claim 2 wherein R<sup>2</sup> is H.

Claim 4. (Original) A compound of claim 2 wherein R<sup>1</sup> is C<sub>1-6</sub>alkyl.

Claim 5. (Original) A compound of claim 2 wherein  $R^1$  is methyl.

Claim 6. (Original) A compound of claim 4 wherein X is  $NR^3$ .

Claim 7. (Original) A compound of claim 6 wherein  $R^3$  is  $C(=O)R^5$ , or  $C(=O)OR^5$ .

Claim 8. (Original) A compound of claim 6 wherein  $R^3$  is  $C(=O)CH_2OH$ .

Claim 9. (Original) A compound of claim 6 wherein  $R^3$  is CHO.

Claim 10. (Original) A compound of claim 7 wherein  $R^5$  is  $C_{1-4}$ alkyl, optionally substituted with  $C(=O)C_{1-4}$ alkyl,  $OC(=O)C_{1-4}$ alkyl,  $C(=O)$ phenyl, or phenyl, wherein said phenyl is optionally substituted with I, or  $CF_3$ .

Claim 11. (Original) A compound of claim 7 wherein  $R^5$  is phenyl.

Claim 12. (Original) A compound of claim 6 wherein  $R^3$  is  $C(=S)R^5$ , wherein  $R^5$  is aryl, alkyl or  $NR^8R^9$ , wherein  $R^8$  and  $R^9$  are independently H,  $C_{1-4}$ alkyl or aryl.

Claim 13. (Original) A compound of claim 6 wherein  $R^3$  is  $S(=O)_iC_{1-4}$ alkyl,

Claim 14. (Original) A compound of claim 6 wherein  $R^3$  is H,  $C_{1-8}$ alkyl, or aryl, .

Claim 15. (Original) A compound of claim 6 or 7 wherein m is 1 and n is 3.

Claim 16. (Original) A compound of claim 6 or 7 wherein m is 2 and n is 2.

Claim 17. (Original) A compound of claim 6 or 7 wherein m is 0 and n is 4.

Claim 18. (Original) A compound of claim 6 or 7 wherein m is 1 and n is 2.

Claim 19. (Original) A compound of claim 6 or 7 wherein m is 2 and n is 1.

Claim 20. (Original) A compound of claim 4 wherein X is S, SO, or SO<sub>2</sub>.


Claim 21. (Original) A compound of claim 4 wherein X is O.

Claim 22. (Original) A compound of claim 20 or 21 wherein m is 1 and n is 2.

Claim 23. (Original) A compound of claim 20 or 21 wherein m is 2 and n is 1.

Claim 24. (Original) A compound of claim 20 or 21 wherein m is 2 and n is 2.


Claim 25. (Original) A compound of claim 1 which is a compound of formula IB:



IB


wherein A is O, S or NH and het is isoxazol-3-yl, isoxazol-5-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl, 1,2,4-thiadiazol-3-yl or 1,2,5-thiadiazol-3-yl.

Claim 26. (Original) A compound of claim 1 which is a compound of formula IC:



IC.

Claim 27. (Original) A compound of claim 1 which is a compound of formula ID



ID

wherein A is O, S or NH and het is isoxazol-3-yl, isoxazol-5-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl, 1,2,4-thiadiazol-3-yl or 1,2,5-thiadiazol-3-yl.

Claim 28. (Original) A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of claim 1.

Claim 29. (Original) The method of claim 28 wherein said compound is administered orally, parenterally, transdermally, or topically.

Claim 30. (Original) The method of claim 28 wherein said compound is administered in an amount of from about 0.1 to about 150 mg/kg of body weight/day.

Claim 31. (Original) The method of claim 28 wherein said compound is administered in an amount of from about 3 to about 100 mg/kg of body weight/day.

Claim 32. (Original) The method of claim 28 wherein said infection is skin infection.

Claim 33. (Original) The method of claim 28 wherein the infection is eye infection.

Claim 34. (Original) A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

Claim 35. (Original) The method of claim 28 wherein said compound is administered in an amount of 600mg per day by IV or by oral.

Claim 36. (Original) The method of claim 22 wherein said mammal is human or an animal.

Claim 37. (Original) A compound of claim 1 which is

- a) (-)-methyl 6-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-3,4-dihydro-2(1*H*)-isoquinolinecarboxylate,
- b) (-)-N-[[[(5S)-3-[2-formyl-1,2,3,4-tetrahydro-6-isoquinolinyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- c) (-)-N-[[[(5S)-3-[2-[(acetyloxy)acetyl]-1,2,3,4-tetrahydro-6-isoquinolinyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- d) (-)-N-[[[(5S)-3-[2-[(hydroxy)acetyl]-1,2,3,4-tetrahydro-6-isoquinolinyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- e) (+)-methyl 6-[(5S)-5-[(ethanethioylamino)methyl]-2-oxo-3-oxazolidinyl]-3,4-dihydro-2(1*H*)-isoquinolinecarboxylate,
- f) (+)-N-[[[(5S)-3-[2-formyl-1,2,3,4-tetrahydro-6-isoquinolinyl]-2-oxo-5-oxazolidinyl]methyl]ethanethioamide, or
- g) (+)-N-[[[(5S)-3-[2-[(hydroxy)acetyl]-1,2,3,4-tetrahydro-6-isoquinolinyl]-2-oxo-5-oxazolidinyl]methyl]ethanethioamide.

Claim 38. (Original) A compound of claim 1 which is

- a) (+)-N-[[[(5S)-3-[2-formyl-1,2,3,4-tetrahydro-7-isoquinolinyl]-2-oxo-5-oxazolidinyl]methyl]ethanethioamide, or
- b) (+)-N-[[[(5S)-3-[2-[(hydroxy)acetyl]-1,2,3,4-tetrahydro-7-isoquinolinyl]-2-oxo-5-oxazolidinyl]methyl]ethanethioamide.

Claim 39. (Original) A compound of claim 1 which is

- a) (-)-N-[[[(5S)-3-(3,4-dihydro-1*H*-2-benzopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide,
- b) (+)-N-[[[(5S)-3-(3,4-dihydro-1*H*-2-benzopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]ethanethioamide,

- c) (-)-N-[[[(5S)-3-(3,4-dihydro-1H-2-benzothiopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide,
- d) (+)-N-[[[(5S)-3-(3,4-dihydro-1H-2-benzothiopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]ethanethioamide, or
- e) (+)-N-[[[(5S)-3-(3,4-dihydro-2,2-dioxido-1H-2-benzothiopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]ethanethioamide.

Claim 40. (Original) A compound of claim 1 which is

- a) (+)-N-[[[(5S)-3-(3,4-dihydro-1H-2-benzopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]ethanethioamide,
- b) (-)-N-[[[(5S)-3-(3,4-dihydro-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide,
- c) (+)-N-[[[(5S)-3-(3,4-dihydro-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]ethanethioamide,
- d) (+)-N-[[[(5S)-3-(3,4-dihydro-2,2-dioxido-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]ethanethioamide, or
- e) N-[[[(5S)-3-(3,4-dihydro-2-oxido-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide.

Claim 41. (Original) A compound of claim 1 which is

- a) N-[[[(5S)-3-(3-formyl-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide,
- b) N-[[[(5S)-3-(3-glycoloyl-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide,
- c) benzyl 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate,
- d) N-[[[(5S)-3-(3-glycoloyl-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]ethanethioamide,
- e) N-[[[(5S)-3-(3-acetyl-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide,




- f) methyl 7-((5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate,
- g) N-(((5S)-3-(3-benzoyl-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide,
- h) N-(((5S)-3-[3-(5-amino-1,3,4-thiadiazol-2-yl)-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide
- i) N-(((5S)-3-[3-(methylsulfonyl)-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide,
- j) N-(((5S)-3-[3-(5-methylthio-1,3,4-thiadiazol-2-yl)-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide,
- k) N-(((5S)-3-[3-(5-methyl-1,3,4-thiadiazol-2-yl)-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide,
- l) phenyl 7-((5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate,
- m) N-(((5S)-3-{3-(phenyl)acetyl-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide,
- o) N-(((5S)-3-{3-[5-(formylamino)-1,3,4-thiadiazol-2-yl]-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide,
- p) N-[5-(7-((5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-1,3,4-thiadiazol-2-yl]-2-hydroxyacetamide,
- q) N-(((5S)-3-{3-[(4-iodophenyl)acetyl]-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide,
- r) N-(((5S)-3-{3-[(3-trifluoromethyl)phenyl]acetyl]-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide,
- s) 2-(7-((5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-2-oxoethyl 4-[(dimethylamino)methyl] benzoate,
- t) N-(((5S)-3-{3-[(4-trifluoromethyl)phenyl]acetyl]-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide,
- u) N-(((5S)-2-oxo-3-[3-(5-oxopentanoyl)-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl]-1,3-oxazolidin-5-yl)methyl)acetamide,

- v) N-((5S)-2-oxo-3-[3-(5-oxohexanoyl)-1,2,4,5-tetrahydro-1H-3-benzazepin-7-yl]-1,3-oxazolidin-5-yl)methyl)acetamide,
- x) N-[[[(5S)-3-(2-formyl-1,3,4,5-tetrahydro-1H-2-benzazepin-7-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide,
- w) N-[[[(5S)-3-(2-glycoloyl-1,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide,
- x) benzyl 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,3,4,5-tetrahydro-3H-2-benzazepine-2-carboxylate,
- y) N-[[[(5S)-3-(2-acetyl-1,3,4,5-tetrahydro-1H-2-benzazepin-7-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide,
- z) methyl 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,3,4,5-tetrahydro-3H-2-benzazepine-2-carboxylate,
- aa) 7-[(5S)-5-[(acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]-N-phenyl-1,3,4,5-tetrahydro-2H-2-benzazepine-2-carboxamide,
- bb) N-[[[(5S)-3-(1-formyl-2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide, or
- cc) N-[[[(5S)-3-(1-formyl-2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl]ethanethioamide.

Claim 42. (Original) A compound of claim 1 which is

- a) N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]acetamide,
- b) N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]acetamide,
- c) N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]ethanethioamide, or
- d) N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]ethanethioamide.

Claim 43. (NEW) A compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein

Y is

- a)  $\text{-NHC(=W)R}^1$ ;

X is

- $\text{-NR}^3$ -;

W is

- a) O, or
- b) S;

$\text{R}^1$  is

- a) H,
- b)  $\text{C}_{1-8}$ alkyl,
- c)  $\text{C}_{3-6}$ cycloalkyl,
- d)  $\text{OC}_{1-4}$  alkyl,
- e)  $\text{SC}_{1-4}$  alkyl,
- f)  $\text{NH}_2$ ,
- g)  $\text{NHC}_{1-6}$  alkyl, or
- h)  $\text{N(C}_{1-6} \text{ alkyl)}_2$ ;

$\text{R}^2$  is

- a) H,
- b) halo, or
- c)  $\text{C}_{1-4}$  alkyl;

$\text{R}^3$  is

- a) H,
- b)  $\text{C}_{1-8}$ alkyl,
- c) aryl,

- d) het,
- e)  $C(=W)R^5$ ,
- f)  $C(=O)OR^6$ , or
- g)  $S(=O)_iR^7$ ;

$R^4$  is

- a) H, or
- b)  $C_{1-8}$ alkyl;

$R^5$  is

- a) H,
- b) aryl,
- c) het,
- d)  $NR^8R^9$ , or
- e)  $C_{1-8}$ alkyl;

$R^6$  is

- a)  $C_{1-8}$ alkyl,
- b) aryl, or
- c) het;

$R^7$  is

- a) aryl,
- b) het,
- c)  $NR^8R^9$ , or
- d)  $C_{1-8}$ alkyl;

$R^8$  and  $R^9$  are independently

- a) H,
- b)  $C_{1-8}$ alkyl, or
- c) aryl;

wherein  $>G-E-$  is  $>N-C-$  and Q is a carbon atom;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;

het is a C-linked five- (5) or six- (6) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring;

at each occurrence, alkyl or cycloalkyl is optionally substituted with one or more  $OR^8$ , halo, aryl,  $S(=O)_iR^7$ ,  $C(=W)R^8$ ,  $OC(=O)C_{1-6}alkyl$ , or  $NR^8R^9$ ;


at each occurrence, aryl is optionally substituted with one or more halo, OH,  $CF_3$ ,  $OC_{1-6}alkyl$ , CN,  $C_{1-6}alkyl$ ,  $S(=O)_iR^7$ ,  $C(=W)R^8$ ,  $OC(=O)R^8$ ,  $NHC(=O)R^8$ , or  $NR^8R^9$ ;

at each occurrence, het is optionally substituted with one or more halo, OH,  $CF_3$ ,  $OC_{1-6}alkyl$ , CN,  $C_{1-6}alkyl$ ,  $S(=O)_iR^7$ ,  $C(=W)R^8$ ,  $OC(=O)R^8$ ,  $NHC(=O)R^8$ , or  $NR^8R^9$ , oxo, or oxime;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, 3, or 4; with the proviso that m and n taken together are 3 or 4.

Claim 44. (NEW) A compound of claim 43 which is a compound of formula IA:



IA.

Claim 45. (NEW) A compound of claim 44 wherein  $R^2$  is H.

Claim 46. (NEW) A compound of claim 44 wherein  $R^1$  is  $C_{1-6}alkyl$ .

Claim 47. (NEW) A compound of claim 44 wherein  $R^1$  is methyl.

Claim 48. (NEW) A compound of claim 43 wherein  $R^3$  is  $C(=O)R^5$ , or  $C(=O)OR^5$ .

Claim 49. (NEW) A compound of claim 43 wherein  $R^3$  is  $C(=O)CH_2OH$ .

Claim 50. (NEW) A compound of claim 43 wherein  $R^3$  is CHO.

Claim 51. (NEW) A compound of claim 48 wherein  $R^5$  is  $C_{1-4}$ alkyl, optionally substituted with  $C(=O)C_{1-4}$ alkyl,  $OC(=O)C_{1-4}$ alkyl,  $C(=O)$ phenyl, or phenyl, wherein said phenyl is optionally substituted with I, or  $CF_3$ .

Claim 52. (NEW) A compound of claim 48 wherein  $R^5$  is phenyl.

Claim 53. (NEW) A compound of claim 43 wherein  $R^3$  is  $C(=S)R^5$ , wherein  $R^5$  is aryl, alkyl or  $NR^8R^9$ , wherein  $R^8$  and  $R^9$  are independently H,  $C_{1-4}$ alkyl or aryl.

Claim 54. (NEW) A compound of claim 43 wherein  $R^3$  is  $S(=O)_iC_{1-4}$ alkyl,

Claim 55. (NEW) A compound of claim 43 wherein  $R^3$  is H,  $C_{1-8}$ alkyl, or aryl.

Claim 56. (NEW) A compound of claim 43 wherein m is 1 and n is 3.

Claim 57. (NEW) A compound of claim 43 wherein m is 2 and n is 2.

Claim 58. (NEW) A compound of claim 43 wherein m is 0 and n is 4.

Claim 59. (NEW) A compound of claim 43 wherein m is 1 and n is 2.

Claim 60. (NEW) A compound of claim 43 wherein m is 2 and n is 1.

Claim 61. (NEW) A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of claim 43.

Claim 62. (NEW) The method of claim 61 wherein said compound is administered orally, parenterally, transdermally, or topically.

Claim 63. (NEW) The method of claim 61 wherein said compound is administered in an amount of from about 0.1 to about 150 mg/kg of body weight/day.

Claim 64. (NEW) The method of claim 61 wherein said compound is administered in an amount of from about 3 to about 100 mg/kg of body weight/day.

Claim 65. (NEW) The method of claim 61 wherein said infection is skin infection.

Claim 66. (NEW) The method of claim 61 wherein the infection is eye infection.

Claim 67. (NEW) A pharmaceutical composition comprising the compound of claim 43 and a pharmaceutically acceptable carrier.

Claim 68. (NEW) The method of claim 61 wherein said compound is administered in an amount of 600mg per day by IV or by oral.

Claim 69. (NEW) The method of claim 61 wherein said mammal is human or an animal.